Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
Date:11/5/2009

PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2009.

Total revenues for the third quarter of 2009 were $30.8 million, compared to $17.7 million for the quarter ended September 30, 2008. XYREM® (sodium oxybate) oral solution net sales for the third quarter of 2009 were $25.0 million, compared to $14.2 million for the third quarter of 2008, and represented a 12% sequential increase over net sales of $22.4 million for the second quarter of 2009. Net sales of once-daily LUVOX CR® (fluvoxamine maleate) extended-release capsules were $5.0 million for the third quarter of 2009, compared to $2.0 million for the third quarter 2008, and represented a 20% sequential increase over net sales of $4.1 million for the second quarter of 2009. Total revenues for the third quarter of 2009 also included $0.8 million in royalties and contract revenue.

"Our sales team delivered another solid quarter for us with record numbers of XYREM and LUVOX CR prescriptions and net sales" said Bob Myers, President of Jazz Pharmaceuticals.

Research and development expenses for the third quarter of 2009 were $7.6 million, compared to $12.1 million for the third quarter of 2008. This reduction from $11.2 million for the second quarter of 2009 was primarily due to the completion of the second Phase III pivotal clinical efficacy trial for JZP-6, sodium oxybate for the treatment of fibromyalgia, in June of 2009. Jazz Pharmaceuticals expects to submit a New Drug Application for JZP-6 by the end of 2009.

Jazz Pharmaceuticals' net loss for the third quarter of 2009 was $1.7 million, compared to a net loss of $28.8 million for the third quarter of 2008.

Jazz Pharmaceuticals is increasing its full-year 20
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
... About 20,000 children in the United States under the ... For many, the disease goes beyond painful red, dry ... equally life altering—with nearly 50 percent of children reporting ...  The XTRAC® Excimer Laser ( www.XTRACLaser.com ) offers new hope ...
Cached Medicine Technology:BioMarin to Present at the William Blair Growth Stock Conference 2XTRAC Laser Provides New Hope for Children with Psoriasis 2XTRAC Laser Provides New Hope for Children with Psoriasis 3
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... , MONDAY, Feb. 27 (HealthDay News) -- Rapid diagnostic ... flu season could lead to earlier treatment for patients and ... suggest. The 2012 flu season is just beginning and, ... 5 million people worldwide, experts say. Most patients will recover, ...
... news digest: , Summary of a study being ... Clinical Oncology , showing that women who underwent a once-common ... slightly lower on cognitive tests that measure word learning, memory ... cancer. While CMF is no longer the standard ...
... MONDAY, Feb. 27 (HealthDay News) -- If a luxurious-looking car ... That,s the message of a new observational study that contends ... cut off pedestrians and ignore stop-sign etiquette. The new ... experiments done by the researchers found that study participants ...
... By Jenifer Goodwin HealthDay Reporter , SUNDAY, Feb. ... cells from adult human ovaries that can mature into eggs ... which upend longstanding scientific theory, could potentially lead to ... woman,s fertility. It was long believed that women were ...
... -- A second company has issued a voluntary recall of ... lead to incorrect dosing and expose women to unintended pregnancies. ... control pill packets, sold as Norgestimate and Ethinyl Estradiol, do ... these oral contraceptives should immediately switch to another form of ...
... TAK-875, a new treatment for type 2 diabetes, improves blood ... a significantly lower risk of creating a dangerous drop in ... The results of the phase 2 randomized trial were published ... 2 diabetes is the most common form of diabetes accounting ...
Cached Medicine News:Health News:Rapid Flu Tests a Good First Step: Study 2Health News:First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen 2Health News:First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen 3Health News:First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen 4Health News:Are the Rich Really Different From You and Me? 2Health News:Are the Rich Really Different From You and Me? 3Health News:Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs 2Health News:Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs 3Health News:Another Batch of Birth Control Pills Recalled for Faulty Packaging 2Health News:Another Batch of Birth Control Pills Recalled for Faulty Packaging 3Health News:Diabetes drug gets patients with Type 2 diabetes on target 2
... and 4 metal chest electrodes on ... procedure enabling a patient to easily ... ECG through a simple change of ... per lead and 10 seconds of ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
... The Digital-Photo Adapter ... designed optics for the ... technology. In combination with ... this is the best ...
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
Medicine Products: